Mar 23, 2023 · Myelodysplastic Syndromes and Secondary AML– Update on Diagnosis and Treatment Low-Risk MDS – Namrata Chandhok, MD, Assistant Professor, Sylvester …

Nov 8, 2024 · This symposium session provides updates on the most recent advances in the pathophysiology diagnosis and clinical management of MDS and AML.

Myelodysplastic syndrome (MDS) comprises a very heterogeneous group of myeloid malignancies with very distinct natural histories. 1 MDS occurs in 3–4 individuals per 10 5 in …

Jun 8, 2023 · The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to …

Importance Myelodysplastic neoplasms (MDS), formerly known as myelodysplastic syndromes, are clonal hematopoietic malignancies that cause morphologic bone marrow dysplasia along …

Jun 16, 2025 · About the Phase 3 VERONA Trial VERONA is a global Phase 3 randomized, controlled trial comparing the efficacy and safety of venetoclax in combination with azacitidine …

Nov 15, 2022 · The rate of sMDS following CLL (including treatment-naïve CLL) has been reported as high as 3.5%. Developing in elderly populations, both CLL and MDS are …

May 25, 2020 · The most recent FDA therapies approved for the treatment of MDS were decitabine (May 2006), lenalidomide (June 2005), and azacitidine (November 2004). This …

Feb 3, 2025 · The International Consensus Classification (ICC) of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) expands on the work of prior classifications to refine …

5 days ago · Myelodysplastic syndromes (MDS) is a heterogeneous group of pre-leukemic diseases characterized by peripheral blood cytopenia, morphologic dysplasia, and an …